🚀 VC round data is live in beta, check it out!
ACROBiosystems Valuation Multiples
Discover revenue and EBITDA valuation multiples for ACROBiosystems and similar public comparables like GNI Group, Guangzhou Innogen Pharma, Septerna, Savara and more.
ACROBiosystems Overview
About ACROBiosystems
Acrobiosystems Co Ltd is a global brand focusing on protein technology, products and services in the development of biological drugs. It is committed to providing target antigens and other key reagents and related services required in the development of targeted therapeutic drugs.
Founded
2010
HQ
Employees
N/A
Website
Financials (LTM)
EV
$913M
ACROBiosystems Financials
ACROBiosystems reported last 12-month revenue of $129M and EBITDA of $40M.
In the same LTM period, ACROBiosystems generated $116M in gross profit, $40M in EBITDA, and $30M in net income.
Revenue (LTM)
ACROBiosystems P&L
In the most recent fiscal year, ACROBiosystems reported revenue of $95M and EBITDA of $27M.
ACROBiosystems expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $129M | XXX | $95M | XXX | XXX | XXX |
| Gross Profit | $116M | XXX | $86M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | $40M | XXX | $27M | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 28% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $30M | XXX | $18M | XXX | XXX | XXX |
| Net Margin | 23% | XXX | 19% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ACROBiosystems Stock Performance
ACROBiosystems has current market cap of $1B, and enterprise value of $913M.
Market Cap Evolution
ACROBiosystems' stock price is $7.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $913M | $1B | -2.4% | XXX | XXX | XXX | $0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialACROBiosystems Valuation Multiples
ACROBiosystems trades at 7.1x EV/Revenue multiple, and 22.8x EV/EBITDA.
EV / Revenue (LTM)
ACROBiosystems Financial Valuation Multiples
As of April 18, 2026, ACROBiosystems has market cap of $1B and EV of $913M.
Equity research analysts estimate ACROBiosystems' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ACROBiosystems has a P/E ratio of 39.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $913M | XXX | $913M | XXX | XXX | XXX |
| EV/Revenue | 7.1x | XXX | 9.7x | XXX | XXX | XXX |
| EV/EBITDA | 22.8x | XXX | 34.3x | XXX | XXX | XXX |
| EV/EBIT | 31.9x | XXX | 56.5x | XXX | XXX | XXX |
| EV/Gross Profit | 7.8x | XXX | 10.6x | XXX | XXX | XXX |
| P/E | 39.5x | XXX | 64.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (96.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ACROBiosystems Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ACROBiosystems Margins & Growth Rates
ACROBiosystems' revenue in the last 12 month grew by 23%.
ACROBiosystems' rule of 40 is 58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ACROBiosystems' rule of X is 94% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
ACROBiosystems Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 37% | XXX | 34% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 58% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 94% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 30% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 16% | XXX | 16% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 26% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 74% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ACROBiosystems Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ACROBiosystems | XXX | XXX | XXX | XXX | XXX | XXX |
| GNI Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Guangzhou Innogen Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Septerna | XXX | XXX | XXX | XXX | XXX | XXX |
| Savara | XXX | XXX | XXX | XXX | XXX | XXX |
| Evotec | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ACROBiosystems M&A Activity
ACROBiosystems acquired XXX companies to date.
Last acquisition by ACROBiosystems was on XXXXXXXX, XXXXX. ACROBiosystems acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ACROBiosystems
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialACROBiosystems Investment Activity
ACROBiosystems invested in XXX companies to date.
ACROBiosystems made its latest investment on XXXXXXXX, XXXXX. ACROBiosystems invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ACROBiosystems
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ACROBiosystems
| When was ACROBiosystems founded? | ACROBiosystems was founded in 2010. |
| Where is ACROBiosystems headquartered? | ACROBiosystems is headquartered in China. |
| Is ACROBiosystems publicly listed? | Yes, ACROBiosystems is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of ACROBiosystems? | ACROBiosystems trades under 301080 ticker. |
| When did ACROBiosystems go public? | ACROBiosystems went public in 2021. |
| Who are competitors of ACROBiosystems? | ACROBiosystems main competitors are GNI Group, Guangzhou Innogen Pharma, Septerna, Savara. |
| What is the current market cap of ACROBiosystems? | ACROBiosystems' current market cap is $1B. |
| What is the current revenue of ACROBiosystems? | ACROBiosystems' last 12 months revenue is $129M. |
| What is the current revenue growth of ACROBiosystems? | ACROBiosystems revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of ACROBiosystems? | Current revenue multiple of ACROBiosystems is 7.1x. |
| Is ACROBiosystems profitable? | Yes, ACROBiosystems is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ACROBiosystems? | ACROBiosystems' last 12 months EBITDA is $40M. |
| What is ACROBiosystems' EBITDA margin? | ACROBiosystems' last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of ACROBiosystems? | Current EBITDA multiple of ACROBiosystems is 22.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.